Trial Profile
An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients: a Phase II Study of the Intergroupe Francophone du Myélome "IFM 2018-04"
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 12 Dec 2023 Primary endpoint has been met. (Percentage of patients receiving the second Autologous Stem Cell Transplant), as per Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 17 Jun 2022 Results of a efficacy and safety analysis of Dara-KRD induction presented at the 27th Congress of the European Haematology Association